Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
Ionis Pharmaceuticals EVP, CLO & General Counsel Patrick R. O'Neil reported an equity award vesting and a share sale. On 01/29/2026 he acquired 11,991 shares of common stock at $0.0 upon vesting of performance-based RSUs, after the Compensation Committee certified performance at 167.27% of target shares. On 01/30/2026 he sold 6,179 common shares at a weighted average price of $83.5335 per share in multiple trades between $83.48 and $83.67. Following these transactions, he directly owned 71,983 Ionis common shares.
Ionis Pharmaceuticals CEO Brett P. Monia reported two stock transactions. On January 29, 2026, he acquired 122,214 shares of common stock at $0.00 upon vesting of performance-based restricted stock units. These PRSUs vested at 167.27% of target, based on Ionis’s relative total shareholder return versus a peer group.
On January 30, 2026, Monia sold 62,970 shares of Ionis common stock at a weighted average price of $82.7216, from multiple trades between $82.26 and $82.925. After these transactions he directly owned 283,927 shares of Ionis common stock.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported two stock transactions. On January 29, 2026, she acquired 13,562 shares of common stock at $0.00 per share from the vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target shares. On January 30, 2026, she sold 6,988 shares of common stock at a weighted average price of $83.243 per share, with individual sale prices ranging from $83.11 to $83.32. Following these transactions, she directly owned 132,881 shares of Ionis Pharmaceuticals common stock.
Ionis Pharmaceuticals executive Brian Birchler reported an equity award and a share sale. On 01/29/2026, he acquired 11,991 shares of common stock at $0.0 per share upon vesting of performance-based restricted stock units tied to relative total shareholder return, which vested at 167.27% of target.
On 01/30/2026, Birchler sold 6,179 common shares at a weighted average price of $83.0309, in multiple trades between $83.00 and $83.08. After these transactions, he directly owned 66,247 Ionis shares as EVP, Corp and Development Ops.
Ionis Pharmaceuticals executive C. Frank Bennett reported a mix of equity vesting and share sales. On January 29, 2026, he acquired 11,421 shares of common stock at $0.0 upon vesting of performance-based restricted stock units. The Compensation Committee certified performance at 167.27% of target shares based on relative total shareholder return versus a peer group, within a possible payout range of 0% to 200%.
On January 30, 2026, Bennett sold 5,885 shares of common stock at a weighted average price of $82.9466, from multiple trades between $82.94 and $82.95. After these transactions, he directly owned 100,293 shares of Ionis common stock.
Ionis Pharmaceuticals executive Joseph Baroldi, EVP and Chief Business Officer, reported equity compensation and a stock sale. On January 29, 2026, he acquired 10,278 shares of common stock at $0.0 upon vesting of performance-based restricted stock units, after performance was certified at 167.27% of target shares based on relative total shareholder return.
On January 30, 2026, he sold 5,296 shares of Ionis common stock at a weighted average price of $82.9615 per share, in multiple trades between $82.95 and $82.97. After these transactions, he held 45,413 shares directly, plus 4,772 shares indirectly through his spouse.
A holder of common stock has filed a Form 144 notice to sell 85,089 shares through Stifel Nicolaus & Company on the Nasdaq market. The filing lists an aggregate market value of $7,056,227 for this planned sale, with 161,974,393 shares outstanding for the issuer.
The seller, identified as Frank Bennett, acquired 65,089 shares via an option exercise dated 01/03/2022 and 20,000 shares through restricted stock units dated 01/15/2017. In the past three months, he has already sold 5,885 and 8,977 shares of common stock for gross proceeds of $487,898 and $684,264, respectively.
Ionis Pharmaceuticals had a Form 144 notice filed for the potential sale of 5,296 shares of its common stock through Morgan Stanley Smith Barney on or about 01/30/2026. The filing lists an aggregate market value of $439,693.50 for these shares on Nasdaq.
The shares to be sold were acquired on 01/29/2026 as performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. The notice states that 161,974,393 shares of common stock were outstanding and discloses a prior sale of 6,907 shares for $523,205.25 on 01/16/2026.
A holder of Ionis Pharmaceuticals common stock filed a notice of proposed sale of 6,179 shares under Rule 144. These shares have an aggregate market value of 512,271.93 and will be sold through Morgan Stanley Smith Barney on the NASDAQ, with an approximate sale date of 01/30/2026.
The securities were acquired as performance stock units granted under Ionis’ 2011 Equity Incentive Plan on 01/29/2026, with compensation as the form of payment. The notice also discloses a prior sale of 8,480 common shares on 01/16/2026 for gross proceeds of 636,932.80, and states that 161,137,930 common shares were outstanding.
Ionis Pharmaceuticals reported a planned sale of 5,885 shares of its common stock under Rule 144. The shares, with an aggregate market value of $487,897.77, are expected to be sold on or about January 30, 2026 through Morgan Stanley Smith Barney on NASDAQ.
The seller acquired these 5,885 shares on January 29, 2026 via performance stock units granted under the company’s 2011 Equity Incentive Plan as compensation. During the prior three months, 8,977 Ionis common shares were also sold, generating gross proceeds of $674,621.55.